ChenyuLinMD

Hematologic Oncology

Assistant Professor of Medicine at Duke University

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Duke University HospitalFellowship, Hematology and Medical Oncology, 2020 - 2023
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2016 - 2019
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2016, M.D.
Yale UniversityB.S., Molecular Biophysics & Biochemistry, 2008 - 2012

PubMed

2 citations
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, Chenyu Lin, Simone E Dekker
Journal of Clinical Oncology. 2025-02-10
2 citations
Siltuximab for chimeric antigen receptor T-cell therapy-related CRS and ICANS: a multicenter retrospective analysis.
Amneet Bajwa, Qiuhong Zhao, Marcus Geer, Chenyu Lin, James Westholder
Blood Advances. 2025-01-14
2 citations
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10

Lectures

Long-Term Antithrombotic Therapy after Venous Stent Placement
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Gamida Cell Announces Results of New Health Economic and Outcome Study Reporting Improved Health EquityApril 25th, 2022
Gamida Cell Announces Data to Be Presented at 2022 Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR Tandem MeetingsJanuary 7th, 2022